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ABSTRACT
Metastasis is the most lethal hallmark of esophageal squamous cell carcinoma 
(ESCC). The aim of the study is to identify key signaling pathways that control 
metastasis in ESCC. Highly invasive ESCC sublines (designated I3 cells) were 
established through three rounds of selection of cancer cells invading through 
matrigel-coated chambers. Gene expression profile of one of the I3 sublines was 
compared with that of its parental cell line using cDNA microarray analysis. Gene 
ontology and pathway analyses of the differentially expressed genes (both upregulated 
and downregulated) indicated that genes associated with cellular movement and the 
AKT pathway were associated with increased cancer cell invasiveness. Western blot 
analysis confirmed increased phosphorylated AKT (p-AKT), N-cadherin and decreased 
E-cadherin expression in the I3 cells. Immunohistochemistry was used to evaluate 
the clinical significance of p-AKT expression in ESCC, and the results showed higher 
p-AKT nuclear expression in lymph node metastases when compared with primary 
carcinoma. Inactivation of the PI3K/AKT pathway with specific inhibitors, or with 
PTEN overexpression, resulted in reversed cadherin switching and inhibited cancer 
cell motility. Inhibition of the pathway by treatment with wortmannin markedly 
suppressed experimental metastasis in nude mice. Our data demonstrated the 
importance of the PI3K/AKT signaling pathway in ESCC metastasis and support PI3K/
AKT as a valid therapeutic target in treatment of metastatic ESCC.
INTRODUCTION
Esophageal cancer is associated with poor prognosis 
because over 50% of patients with esophageal cancer 
present with metastasis [1]. Cancer metastasis is a multi-
stage process which involves enhanced cell motility, 
intravasation, transit in lymphatic and blood vessels, 
extravasation and finally growth at a new location. Each of 
these events is attributed, at least in part, to the acquisition 
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of genetic alterations in the tumor cells [2]. Identification 
of critical regulators and signaling pathways that drive 
invasion and metastasis will facilitate development of new 
treatment strategies.
In the present study, we established highly invasive 
ESCC sublines (designated I3 cells) by serial selection 
of cancer cells invading through matrigel-coated Boyden 
chambers to explore the mechanisms involved in metastasis 
in ESCC. Bioinformatics analysis of gene expression 
profile of the I3 cells, followed by confirmation of increased 
phosphorylated-AKT (p-AKT) expression in I3 cells and 
in metastatic ESCC in lymph nodes, suggested that the 
phosphatidylinositol-3-kinase (PI3K)/AKT pathway has a 
crucial role in esophageal cancer invasion and metastasis. 
The PI3K/AKT signaling pathway is implicated in a 
variety of oncogenic processes including cell proliferation, 
survival, epithelial mesenchymal transition (EMT), 
enhanced motility, and angiogenesis [3–6]. Our previous 
study demonstrated that pharmacological inhibition of the 
PI3K/AKT pathway can offset the increased invasiveness 
and motility induced by Id1-overexpression in ESCC cells 
[7]. However, the effects of PI3K inhibitors on suppressing 
the metastatic potential of non-transfected ESCC cells 
have not been reported previously and warrant further 
investigation. LY294002 and wortmannin are potent 
PI3K inhibitors that are commonly used in laboratory and 
preclinical studies but have been precluded from clinical 
use due to instability, poor solubility and/or high toxicity. 
Since new evidence supports that the clinical application 
of wortmannin may be revived through nanoparticle 
drug delivery [8], wortmannin was used in this study to 
investigate the effects of PI3K/AKT blockade on in vivo 
metastasis of human ESCC cells in mice. Moreover, 
because increased invasiveness may be conferred by EMT 
during which epithelial markers are usually downregulated 
while mesenchymal markers are upregulated, we also 
examined the expression levels of EMT markers including 
E-cadherin and N-cadherin in ESCC cells (including the 
I3 cells), and determined whether PI3K/AKT inhibition 
by LY294002 and wortmannin could reverse the EMT 
program.
RESULTS
KYSE410-I3 and KYSE510-I3 sublines are 
highly invasive and show increased EMT
The KYSE410-I3 and KYSE510-I3 sublines showed 
significantly higher invasive potential (Figure 1A), 
and enhanced EMT as indicated by marked decrease in 
E-cadherin and increase in N-cadherin expression (Figure 
1B), compared with their respective parental ESCC cell 
lines, although no significant difference in morphology 
was observed (Figure 1C). The comparable proliferation 
rates of the I3 cells and parental cells within a 24-hour 
time frame ruled out the possibility that the increase 
in evaded I3 cells in the cell invasion assay was due to 
increased proliferation (Figure 1D).
Highly invasive esophageal cancer cells 
overexpress p-AKT
The gene expression profiles of KYSE410-I3 and its 
parental cell line were compared using cDNA microarray. 
Of the 246 differentially expressed genes in KYSE410-I3, 
232 (including 63 upregulated and 169 downregulated 
genes (listed in Supplementary Table 1) were mapped to 
known functions and pathways by IPA. Gene Ontology 
(GO) analysis indicated that the differentially expressed 
genes in the I3 cells were significantly associated with 
five important cellular functions including cell movement 
(Figure 2A). Pathway analysis showed that a cluster of 
differentially expressed genes in the I3 cells constitute a 
signaling network with AKT as central hub (Figure 2B), 
thus suggesting dysregulation of AKT signaling in these 
cells. The upregulation and downregulation of representative 
genes including ANKRD1 and TTC3, which were randomly 
selected from the list of differentially expressed genes, 
were confirmed by quantitative RT-PCR (Figure 2C). 
Western blot analysis confirmed upregulation of p-AKT 
expression, and significantly reduced expression level of 
PTEN which is the upstream negative regulator of PI3K/
AKT pathway, in KYSE410-I3 and KYSE510-I3 cells 
(Figure 2D). Interestingly, there was no activation of the Src 
pathway, which is another important regulatory pathway in 
cancer cell invasion and metastasis [9, 10], as indicated by 
the comparable protein expression level of p-Src and Src 
between the I3 sublines and corresponding parental cells 
(Figure 2D), even though the IPA analysis also suggested 
the dysregulation of the Src pathway in KYSE410-I3 cells. 
This further highlighted the significance of PI3K activation 
in esophageal cancer invasion and metastasis.
Inhibition of PI3K/AKT signaling reduces 
esophageal cancer cell invasion and migration
To study whether PI3K/AKT inhibition can 
suppress esophageal cancer cell motility and reverse the 
invasiveness of I3 cells, a vector expressing PTEN was 
transfected into KYSE410-I3 and KYSE510-I3 cells, as 
well as KYSE270 and T.Tn which were ESCC cell lines 
with relatively high invasive ability. Our results showed 
that PTEN overexpression significantly reduced the 
ability of esophageal cancer cells to invade (Figure 3A). 
Treatment with a low concentration (5 μM) of LY294002 
or wortmannin, which had no significant inhibitory effects 
on cell proliferation of these cells within 24 hours [11], 
also markedly inhibited ESCC cell invasion (Figure 3B). 
Likewise, cell migration assays showed that inhibition of 
PI3K/AKT signaling by overexpressing PTEN (Figure 3C) 
or pharmacological blockade (Figure 3D) markedly retarded 
ESCC cell migration.
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Blockade of PI3K/AKT reverses cadherin 
switching
Cadherin switching, which is characterized by 
downregulation of E-cadherin and upregulation of 
N-cadherin expression, is considered a hallmark of 
EMT and cancer invasion [12]. To study whether the 
effects of PI3K/AKT inhibition on esophageal cancer 
cell motility were associated with changes in E-cadherin 
and N-cadherin expressions, the esophageal cancer 
cells transfected with PTEN or treated with PI3K/AKT 
inhibitors were analyzed by Western blot. The increase in 
E-cadherin and decrease in N-cadherin expression levels 
upon PI3K/AKT inhibition suggests that the effects of 
PI3K/AKT blockade on esophageal cancer cell mobility 
were due to reversal of EMT (Figure 4A and 4B).
Wortmannin suppresses metastasis of esophageal 
cancer cells in nude mice
Since our results showed that PI3K/AKT inhibition 
reduced the migration and invasive potential of 
esophageal cancer cells in vitro (Figure 3), we evaluated 
the efficacy of PI3K/AKT blockade in inhibiting 
metastasis of esophageal cancer cells in vivo. Nude 
mice were intravenously inoculated with luciferase-
expressing esophageal cancer cells, and treated with 
different doses of wortmannin. Bioluminescent imaging 
and histological examination of the lungs demonstrated 
that wortmannin treatment significantly suppressed the 
metastatic colonization of esophageal cancer cells to the 
lungs in a dose-dependent manner (Figure 5A, 5B and 
5C). Moreover, the suppressive effect of wortmannin 
on metastasis was confirmed by the lower expression 
Figure 1: Establishment of highly invasive ESCC sublines. (A) Matrigel chamber invasion assay comparing the invasive potential 
of KYSE410-I3 and KYSE410-I3 sublines with that of corresponding parental cells. The quantification data show dramatic increase in 
invasive potential of I3 cells. (B) Comparison of E-cadherin and N-cadherin expressions in I3 cells and parental cells. (C) Morphology of 
I3 cells and parental cells. (D) Parental and I3 cells had similar proliferation rates as determined by MTT assay. Bars, SD; **, P < 0.01; 
***, P < 0.001 compared with control cells.
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of human-specific cytokeratin-8 (expressed by human 
ESCC cells) in the lung extracts of wortmannin-treated 
mice compared with the control group (Figure 5D). The 
presence of bioluminescent signals in the tail region of 
some of the animals in the wortmannin treatment groups 
could be due to proliferation of small number of injected 
cancer cells which had leaked into the surrounding tissue 
during or after tail vein injection, but were subsequently 
inhibited from entering the circulation and undergoing 
metastatic seeding by the anti-invasive and anti-migratory 
effects of wortmannin.
PI3K/AKT pathway is constitutively activated in 
lymph node metastases of ESCC
To determine whether PI3K/AKT activation is 
clinically relevant in the pathogenesis of lymph node 
metastasis in ESCC, the expression level of p-AKT in 
ESCC tissue was determined immunohistochemically. 
Positive staining was mainly detected in the nuclei of 
cancer cells in the primary carcinoma and in lymph node 
metastases (Figure 6A). Among 28 cases of primary 
tumors, only 5 cases had high p-AKT nuclear expression, 
compared to 7 out of 15 cases of lymph node metastases 
(P = 0.045), indicating that there was a higher percentage 
of ESCC cells with activated AKT in the lymph node 
metastases than in the primary tumors (Figure 6B). 
These data highlighted the significance of PI3K/AKT 
signaling pathway in metastasis in ESCC and its potential 
as therapeutic target in cancer treatment. However, 
analysis of p-AKT expression in a tissue microarray 
(TMA) containing primary ESCC tissues did not yield 
any significant correlation with TNM pathological staging 
(Supplementary Table 2).
DISCUSSION
Cancer metastases, rather than the primary cancer, 
account for as high as 90% of cancer death [13, 14]. Recent 
advances in gene profiling techniques and establishment 
Figure 2: Highly invasive ESCC cells exhibit PI3K/AKT activation. (A) GO analysis of cDNA microarray data from KYSE410-I3 
cells and KYSE410 cells. (B) Ingenuity Pathway Analysis (IPA)indicated a dysregulation of AKT signaling in I3 cells. (C) Comparison 
of mRNA expression levels of ANKRD6 and TTC3 in I3 cells and corresponding parental cells by qRT-PCR. (D) Western blot analysis of 
expression levels of p-AKT, AKT, PTEN, p-Src and Src in I3 sublines and corresponding parental cells.
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Figure 3: Inhibition of PI3K/AKT pathway suppresses esophageal cancer cell invasion and migration. (A) Human 
esophageal cancer cells KYSE270, T.Tn, KYSE410-I3 and KYSE510-I3 with PTEN overexpression were subjected to invasion assay. 
Values were then normalized to cells expressing vector control (CON). (B) Treatment with 5 μM LY294002 or 5 μM wortmannin reduced 
the invasive potential of KYSE270, T.Tn, KYSE410-I3, and KYSE510-I3 cells as determined by chamber invasion assay. (C) PTEN 
overexpression inhibited cell migration in KYSE270 and T.Tn cells as determined by chamber migration assay. (D) PI3K/AKT inhibitors, 
LY294002 and Wortmannin, significantly suppressed cancer cell migration in KYSE270 and T.Tn cells. Bars, SD; **, P < 0.01; ***, P < 
0.001 compared with control cells.
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of metastatic cell models have been instrumental in 
identifying genes and pathways associated with tumor 
metastasis [15]. To our knowledge, this is the first study 
that compares the gene profiles of highly invasive ESCC 
cells and the relatively non-invasive parental cells. The 
highly invasive ESCC sublines that were established in 
this study not only confirms the significance of the PI3K/
AKT pathway in ESCC metastasis, but will be valuable 
tools for evaluating novel therapeutic agents which can 
curb tumor metastasis.
Although the PI3K/AKT signaling pathway is 
well documented to drive EMT, invasion and metastasis 
Figure 4: Effects of PI3K/AKT blockade on E-cadherin and N-cadherin expressions in esophageal cancer cells. (A) 
Western blot analysis showed that PTEN overexpression in KYSE270, T.Tn, KYSE410-I3, and KYSE510-I3 cells increased the expression 
level of E-cadherin and decreased N-cadherin. Actin was included as internal loading control. (B) Western blot analysis of protein 
expressions of E-cadherin and N-cadherin in esophageal cancer cells treated with wortmannin or LY294002 for 24 h compared with the 
DMSO-treated cells.
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Figure 5: Effect of wortmannin treatment on metastasis of ESCC cells in nude mice. (A-C) Human esophageal cancer cells 
with ectopic luciferase (Luc) expression, KYSE150-Luc, were intravenously injected into nude mice through the tail vein. The mice were 
treated with 0.3 mg/kg or 0.6 mg/kg wortmannin, or DMSO twice a week. (A) Bioluminescent imaging of luciferase-expressing esophageal 
cancer cells eight weeks later. (B) Quantification of bioluminescent signals by Living Image software. Note that treatment with wortmannin 
significantly reduced the metastatic activity of esophageal cancer cells in a dose-dependent manner. (C) Micrometastases in the lungs were 
detected histologically. (D) The lung extracts from wortmannin-treated mice were compared with those of DMSO-treated mice for human-
specific cytokeratin-8 expression level by western blot. Bars, SD; *, P < 0.05; **, P < 0.01 compared with DMSO-treated mice.
Figure 6: Constitutive activation of PI3K/AKT in lymph node metastases of ESCC. (A) Representative immunohistochemical 
images of p-AKT expression (x 20 magnification) in primary ESCC and lymph node metastases. Note that the lymphocytes were also 
positively-stained. (B) Pearson’s Chi-Square test showed significantly higher p-AKT expression in metastatic carcinoma compared with 
primary tumors.
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in human cancer [16–20], there are surprisingly few 
reports on its physiological significance in metastasis of 
ESCC. The metastasis-promoting function of Id1, MMP-
1, integrin alpha6 and PITX2, for example, requires 
activation of the PI3K/AKT pathway [7, 21–23]. Here, 
our results showed that p-AKT expression was increased 
in the highly invasive esophageal cancer sublines and 
was likely due to downregulation of PTEN. Loss of 
E-cadherin, the key gatekeeper of the epithelial state, is 
necessary for the EMT process, and has been associated 
with cancer progression and poor prognosis in ESCC [24, 
25]. N-cadherin, a mesenchymal cadherin associated with 
EMT, promotes tumor cell invasion and metastasis, and 
its high expression is associated with metastasis in ESCC 
[26–28]. Notably, E-cadherin to N-cadherin switching is 
necessary for increased motility though not required for 
morphological changes that accompany EMT [29]. We 
found that pharmacological and genetic blockade of PI3K/
AKT pathway significantly inhibited migration and invasion 
in esophageal cancer cells, accompanied by upregulation 
of E-cadherin and downregulation of N-cadherin. The 
mechanisms by which activation of the PI3K/AKT pathway 
induces cadherin switching warrant further investigation, but 
previous studies have provided some clues. It was reported 
that E-cadherin is repressed by NFκB, the downstream 
pathway of PI3K/AKT signaling, and that this effect is 
mediated by multiple transcriptional regulators of E-cadherin 
including the Snail family of transcriptional repressors, Snail 
and Slug [30], and the ZEB family members, ZEB1 and 
ZEB2 [31]. In addition, PI3K/AKT can upregulate mRNA 
expression of N-cadherin through transcriptional regulation 
of Twist and Snail [32, 33].
Several lines of evidence indicate that translocation 
of activated/phosphorylated AKT to the nucleus is 
important for regulation of signaling pathways involved 
in proliferation and survival of cancer cells [34]. Our 
immunohistochemical evaluation of primary ESCC showed 
no significant correlation between p-AKT nuclear expression 
and pathological stage, which was consistent with what was 
described in two recent studies [35, 36] reporting that low 
p-AKT alone or concurrent high EGFR and low p-AKT 
expression is associated with better outcome in esophageal 
cancer patients who received chemotherapy, but p-AKT 
alone may not be an ideal predictor of survival for patients 
without chemotherapy. Although our results showed a lack 
of correlation between p-AKT expression and M-stage, 
which could be due to the small number of cases with distant 
metastasis (n = 2) in our sample cohort, a significantly 
higher p-AKT expression was found in metastatic ESCC 
in lymph nodes, suggesting that PI3K/AKT activation 
is critical for metastatic colonization which is one of the 
most ominous features of cancer progression [37]. Since 
cancer cells are frequently present in the blood and distant 
organs of cancer patients at initial presentation, it has been 
suggested that the capability of therapeutic agents to impair 
proliferation of already disseminated cancer cells should be 
a key consideration in drug design [2]. Unfortunately, many 
of the current compounds in clinical trials and preclinical 
studies such as matrix metalloproteinases inhibitors and 
Axl kinase inhibitor act principally by blocking the escape 
of cancer cells from primary tumors [38]. The experimental 
metastasis model used in the present study in which 
intravenously injected cancer cells colonized distant organs 
to form micro- and macro-metastases best mimics the most 
crucial and selective steps of metastasis. We have provided 
direct evidence that treatment with PI3K/AKT inhibitor can 
significantly suppress metastasis of ESCC cells in an in vivo 
setting.
Emerging evidence suggests that tumor 
microenvironment and angiogenesis also play critical 
roles in metastasis [39–41]. A recent study showed 
that the binding of tumor-associated macrophages to 
cancer cells through vascular cell adhesion molecule 1 
(VCAM1) activates AKT signaling and protects cancer 
cells from apoptosis in the lung microenvironment 
[42]. Collectively, these evidences support the rationale 
for PI3K/AKT blockade to suppress micrometastasis 
formation and metastatic colonization. Further studies 
on the efficacy of PI3K/AKT blockade in preventing 
the earlier steps of metastasis in ESCC will enhance our 
understanding of the role of PI3K/AKT pathway in this 
process. However, unlike breast [43], lung [44], and liver 
cancers [45] in which spontaneous metastasis mouse 
models are commonly used to mimic all the steps of 
tumor metastasis, such models are not readily available 
for ESCC. In summary, our results confirm the importance 
of the PI3K/AKT pathway in metastasis and support its 
potential applicability as a therapeutic target in ESCC.
MATERIALS AND METHODS
Cell culture and drugs
Human ESCC cell lines KYSE150, KYSE270, 
KYSE410 and KYSE510 obtained from DSMZ 
(Braunschweig, Germany) [46], and T.Tn obtained from 
Dr. Hitoshi Kawamata (Dokkyo University School of 
Medicine, Tochigi, Japan) [47], were maintained in RPMI 
1640 (Sigma, St. Louis, MO, USA) supplemented with 
10% fetal bovine serum (Invitrogen, Gaithersburg, MD, 
USA) at 37°C in 5% CO2. Wortmannin and LY294002 
were purchased from Calbiochem (Darmstadt, Germany) 
and dissolved in dimethyl sulfoxide (DMSO).
Establishment of highly invasive esophageal 
cancer sublines
Esophageal squamous cell carcinoma cell lines 
KYSE410 and KYSE510, which had relatively weak 
invasive ability, were seeded into the upper compartment 
(4 x 105 cells/well) of an 8 μm pore size BioCoat Matrigel 
Invasion chamber (BD Biosciences, Bedford, MA, 
USA) and incubated for 48 h. The cells that invaded and 
adhered on the lower surface of chamber were detached 
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with trypsin and cultured until the number of cells was 
adequate for the next round of invasion selection, then the 
cells were re-inoculated into the upper compartment of a 
new invasion chamber. The same procedure was repeated 
three times to select for highly invasive cells designated 
KYSE410-I3 and KYSE510-I3 (Figure 1A, left panel).
cDNA microarray and ingenuity pathway 
analysis (IPA)
Human Genome U133 Plus 2.0 GeneChip 
(Affymetrix Inc., Santa Clara, CA, USA) was used for 
genome-wide mRNA expression profiling. Total RNA 
was isolated using TRIZOL Reagent (Invitrogen), and 
the quality of total RNA was assessed with the Agilent 
2100 Bioanalyzer Platform. Double-stranded cDNA 
was synthesized by reverse transcription from total 
RNA, and then in vitro transcription was performed 
to produce biotin-labeled cRNA from the cDNA. The 
cRNA is fragmented before hybridization. After washing 
and staining with the GeneChip Fluidics Station 450 
(Affymetrix), the genechips were scanned with the 
GeneChip Scanner 3000 (Affymetrix). Scanned output 
files were analyzed with GeneSpring GX 12.0 software 
(Agilent Technologies, Inc., Santa Clara, CA, USA). 
A fold difference of > 2.0 was defined as differentially 
expressed. IPA software (Ingenuity Systems, Redwood 
City, CA, USA) was used for pathway analysis. The Gene 
ID of the differentially expressed genes in KYSE410-I3 
cells and the corresponding fold-change were uploaded 
into IPA software (Ingenuity Systems, Redwood City, CA, 
USA). The Core Analysis tool, Gene Ontology analysis, 
and the Fisher’s Exact Test in IPA were used to identify 
statistically significant associations between differentially 
expressed genes and cellular/molecular pathways. 
We configured the core analysis to report Benjamini–
Hochberg corrected P values.
Transfection and establishment of stable cell 
lines
The plasmid expressing phosphatase and tensin 
homolog (PTEN), i.e. pcDNA3-PTEN [48], and the vector 
control pcDNA3-GFP [49] were gifts from William Sellers 
(Dana Faber Cancer Institute, Boston, MA, USA) and 
Alonzo Ross (University of Massachusetts, Worcester, 
MA, USA), respectively (Addgene plasmids 10759 and 
20738; Addgene, Cambridge, MA, USA). Transfection 
and establishment of stable cell lines were performed as 
described previously [7].
Western blot
Details on preparation of cell and tumor lysates, 
and Western blotting were described previously [50]. 
The primary antibodies used included the following 
purchased from Cell Signaling Technology (Beverly, 
MA, USA): p-AKT (Ser473) and AKT for detecting the 
phosphorylated form and total AKT respectively, PTEN 
for confirming successful ectopic expression of PTEN 
after ESCC cells were transfected with PTEN-expressing 
plasmid, Src and p-Src (Tyr416) for detecting total Src 
protein and its phosphorylation status in order to evaluate 
activation of Src pathway. Primary antibodies against 
E-cadherin (BD Biosciences) and N-cadherin (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) were used to study 
the role of PI3K/AKT in EMT. Antibody against human-
specific cytokeratin-8 (Epitomics, Burlingame, CA, USA) 
was used to detect presence of human cancer cells in the 
lungs of experimental metastasis model. Actin, serving 
as loading control, was detected using an antibody from 
Santa Cruz Biotechnology.
Quantitative real-time PCR
The qRT-PCR was performed as described 
previously [51]. In brief, total RNA was isolated 
using Trizol reagent according to the manufacturer’s 
protocol (Invitrogen). The cDNA was synthesized 
using the PrimeScript™ II 1st Strand cDNA Synthesis 
Kit (Takara, Dalian, China). The mRNA expression 
levels of ANKRD1, TTC3 and of GAPDH as internal 
control, were detected by real-time PCR using 
SYBR® Premix Ex Taq™ II (Takara). The primers 
used were: 5'-ACGCCAAAGACAGAGAAGGA-3' 
(forward) and 5'- CCAGTGTAGCACCAGATCCA-3' 
(reverse) for ANKRD1; 5'-AGCACTGAGCTTGCT 
GGTTT-3' (forward) and 5'-CTTGTCCTTTCCTGGG 
TTTG-3' (reverse) for TTC3; 5'-AAGGTGAAGGTC 
GGAGTCAA-3' (forward) and 5'-GACAAGCTTCCC 
GTTCTCAG-3' (reverse) for GAPDH.
3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay
MTT assay was performed to measure cell viability 
as described before [52].
In vitro cell migration and invasion assays
In vitro cell migration assays were carried out 
with the use of uncoated Transwell chambers (Corning, 
New York, NY) [52]. In vitro cell invasion assays were 
performed with the use of BD BioCoat Matrigel Invasion 
chambers (BD Biosciences) according to manufacturer’s 
instructions [7].
Experimental metastasis assay in nude mice
Female BALB/c nude mice aged 6-8 weeks were 
maintained under standard conditions and cared for 
according to the institutional guidelines for animal care. 
About 1 x 106 KYSE150 cells with ectopic luciferase 
expression (i.e. KYSE150-Luc) were suspended in 
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phosphate buffered saline and injected intravenously 
through the lateral tail vein of the mice [53]. Seven days 
after injection of cancer cells, the animals were treated 
twice weekly with PI3K inhibitor wortmannin (0.3 mg/
kg or 0.6 mg/kg) or vehicle through intraperitoneal 
injection. The treatment regimen was designed based 
on published studies [54, 55] to minimize toxic effects 
on the animals. Metastatic activity was assessed by 
bioluminescent imaging with an IVIS Imaging System 
(Xenogen, Alameda, CA) after intraperitoneal injection 
of D-luciferin (Gold Biotechnology, St Louis, MO). The 
animals were euthanized at the end of the experiment, and 
the lungs were collected for further analyses including 
Western blotting and histological analysis. All the animal 
experiments were approved by the Committee on the 
Use of Live Animals in Teaching and Research of the 
University of Hong Kong.
Tissue samples, tissue microarray and 
immunohistochemistry
Immunohistochemical staining was performed on 
paraffin sections of 28 cases of primary ESCCs and 15 
cases of lymph nodes with metastatic ESCC in order to 
compare p-AKT expression pattern in cancer cells within 
primary tumors against that of metastasized ESCC 
cells. A tissue microarray (TMA) containing a separate 
cohort of 82 cases of primary ESCC (Supplementary 
Table 3) was also included to determine whether p-AKT 
expression is correlated with demographic features of 
patients and clinicopathological parameters. These 
specimens were collected from patients who underwent 
surgical resection of primary esophageal tumor at Queen 
Mary Hospital in Hong Kong, or the First Affiliated 
Hospital, Zhengzhou University in Zhengzhou, China, 
from 1989 to 2004. All clinical samples were obtained 
with informed consent of the patients. Ethical approval 
was also obtained from the Griffith University Human 
Research Ethics Committee (GU Ref Nos: MED/19/08/
HREC and MSC/17/10/HREC) for retrospective use 
of ESCC tissues. The TMA was constructed using a 
Galileo CK3500 tissue Microarrayer (Integrated System 
Engineering Srl, Milano, Italy). Briefly, all representative 
donor blocks of ESCC were cut for haematoxylin & 
eosin staining to define the site of the representative 
regions of ESCC. From those regions, 3 cylindrical core 
tissue specimens (diameter = 0.6 mm) were acquired 
from each ESCC and arrayed into a new recipient 
paraffin block (35 x 20mm2). Paraffin-embedded 
sections and TMAs were deparaffinized in toluene 
and rehydrated in a graded series of ethanol solutions. 
Following antigen retrieval in citrate buffer (pH 6.0) and 
blocking with normal serum, the slides were incubated 
overnight with phospho-AKT (Ser473) antibody 
(Cell Signaling Technology), washed with phosphate 
buffered saline, and then incubated with biotinylated 
secondary antibody for 30 min at room temperature. 
Peroxidase-conjugated avidin-biotin complex was added 
to the sections and 3,3’-diaminobenzidine (Dako) was 
used as chromogen to visualize the immunostaining, 
followed by counterstaining with hematoxylin. The 
immunohistochemical staining for p-AKT nuclear 
expression was classified into four categories: no or 
negligible staining (score 0), weakly positive with less 
than 10% tumor cells stained (score 1+), moderate 
intensity with 10 to 50% cells stained (score 2+), and 
strong staining intensity in > 50% cells (score 3+). 
Cases with scores of 0 or 1+ were grouped as “low” 
expression, whereas those with a score of 2+ or 3+ were 
regarded as having high expression.
Statistical analysis
The data were expressed as the mean ± SD and 
compared using ANOVA. All in vitro experiments were 
repeated at least three times. For the immunohistochemistry 
results, the data were entered into a computer database 
and the statistical analysis was performed using SPSS for 
Windows (version 22.0, IBM SPSS Inc., New York, NY). 
Fisher’s exact test or Pearson Chi-Square was used for 
analyzing the association between expression level p-AKT 
and categorical clinicopathological variables. P values < 
0.05 were deemed significant.
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